The technology was originally developed by combining an anti-HER2 to a sialidase conjugate that selectively removed diverse sialoglycans from breast cancer cells, leading to enhanced immune cell infiltration and activation, as well as prolonged survival, in mouse models [29]. This evidence concerns the gene ERBB2 and breast carcinoma.